Pricing Log in Create free account

Corvus Pharmaceuticals, Inc. (CRVS) vs Prime Medicine, Inc. (PRME)

Corvus Pharmaceuticals, Inc. and Prime Medicine, Inc. are both Biotechnology companies. Corvus Pharmaceuticals, Inc. and Prime Medicine, Inc. are of similar size ($818.5M and $807.1M). Corvus Pharmaceuticals, Inc. has the higher net margin (0.00% vs −4,613.1%) and the lower return on invested capital (−352.5% vs 0.00%). Across the 13 metrics below, Corvus Pharmaceuticals, Inc. leads on 10 and Prime Medicine, Inc. on 3.

Valuation

Metric CRVS PRME Biotechnology median
P/E n/m n/m 10.60
P/S n/m 200.59 9.40
P/B 4.33 20.52 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 177.25 9.02
Earnings yield (5.77%) (23.95%) (32.88%)
Free cash flow yield (4.63%) (19.20%) (23.13%)

Profitability

Metric CRVS PRME Biotechnology median
Gross margin 0.00% 100.00% 68.51%
Operating margin 0.00% (4,824.94%) 0.00%
Net margin 0.00% (4,613.11%) 0.00%
Free cash flow margin 0.00% (3,850.92%) 0.00%
Return on equity (35.43%) (373.29%) (51.96%)
Return on assets (32.93%) (71.16%) (46.06%)
Return on invested capital (352.49%) 0.00% 0.00%

Growth

Metric CRVS PRME Biotechnology median
Revenue growth (TTM) — (17.90%) 6.76%
EPS growth (last fiscal year) 48.04% 18.18% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRVS PRME Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 16.16 3.05 4.97
Net debt to EBITDA 1.28 0.88 1.01

Dividend

Metric CRVS PRME Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CRVS PRME Biotechnology median
Market cap 818.50m 807.12m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack